Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fuji Pharma Co., Ltd. ( (JP:4554) ) has issued an announcement.
Fuji Pharma has recognized an impairment loss on its portfolio of available-for-sale securities for the first quarter of the fiscal year ending September 2026, booking a valuation loss of ¥2,457 million after a significant decline in the share price of Alvotech Holdings S.A., a key partner in its biosimilars growth strategy. The company notes that the valuation of these securities is reassessed quarterly under a wash-up method and may fluctuate with future share price movements, and it has indicated that the impact on its consolidated earnings forecast for the first half and full year to September 2026 is addressed in a separate revision of earnings guidance released the same day, underscoring potential implications for profitability and investor expectations.
The most recent analyst rating on (JP:4554) stock is a Buy with a Yen2093.00 price target. To see the full list of analyst forecasts on Fuji Pharma Co., Ltd. stock, see the JP:4554 Stock Forecast page.
More about Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. is a Japan-based pharmaceutical company, with a strategic focus that includes participation in the global biosimilars market through partnerships such as its investment in Alvotech Holdings S.A., a NASDAQ-listed biosimilars licensor positioned as part of the company’s growth strategy.
Average Trading Volume: 92,419
Technical Sentiment Signal: Buy
Current Market Cap: Yen46.45B
See more insights into 4554 stock on TipRanks’ Stock Analysis page.